First-line use of tepotinib in METex14 NSCLC: A patient-centered journey

I-DXd shows strong brain metastasis responses in extensive-stage small cell lung cancer with manageable safety

Tarlatamab for SCLC: Subgroup analysis shows benefit regardless of previous chemo or anti-PD-(L)1 use

Tarlatamab improves symptoms and QoL over chemo in previously treated SCLC

Tarlatamab improves survival over chemo in 2L SCLC regardless of prior immunotherapy or chemo

Tarlatamab plus chemo-IO shows promising efficacy in extensive stage SCLC

ESMO 2025: Highlights and analysis

ESMO 2025: Latest in EGFR mutant NSCLC

Sacituzumab tirumotecan improves progression-free and overall survival in EGFR-TKI resistant NSCLC

Zongertinib shows high response rates in first-line HER2-mutant advanced NSCLC

Osimertinib plus chemo improves survival across high-risk subgroups in EGFR-mutated aNSCLC

Tarlatamab shows manageable safety profile with fewer toxicities than chemo in 2L SCLC